Biovest seeks Canadian marketing nod for its personalized lymphoma cancer ... pharmabiz.com While combination rituximab-chemotherapy regimens available today often induce tumour remissions in the early stages of treatment, these remissions seldom last; most patients relapse within years after discontinuing treatment. |
